Insights

1
1
2
2
1
1
1
1
1
1
1
1
6
6
6
6
2
2
5
5
2017
2000
Company (27)University (5)Hospital (1)
1 - 10 of 27
Sort by
Publication
PubMed ID28417565Published Date2017-05-01JournalJournal of biophotonics, 2017-05-01, Volume 10
Immunotherapy has become a promising modality for melanoma, especially using checkpoint inhibitors, which revive suppressed T cells against the cancer. Such inhibitors should work better when combined with other treatments which could increase the number and quality of anti-tumor T cells. We treated one patient with advanced (stage IV) melanoma, using the combination of laser immunotherapy (LIT), a novel immunological approach for metastatic cancers that has been shown to stimulate adaptive i…
Patent
Publication NumberAU 2013209716 B2StatusIssued PatentAvailabilityUnknownFiling Date2013-01-17Publication Date2017-04-27
The present invention relates generally to therapeutic compositions comprising chitosan- derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Publication
PubMed ID28028922Published Date2017-04-01JournalJournal of biomedical materials research. Part A, 2017-04-01, Volume 105
Immunotherapy has become one of the fastest growing areas of cancer research. A promising in situ autologous cancer vaccine (inCVAX) uses a novel immune activator, N-dihydrogalactochitosan (GC), that possesses the ability to stimulate dendritic cells (DC). inCVAX is a combination treatment procedure involving treatment of the tumor with a thermal near-infrared laser to liberate whole cell tumor antigens, followed by injection of GC (a glucosamine polymer with galactose attached to the amino g…
Patent
Publication NumberKR 20170032490 AStatusPatent ApplicationAvailabilityUnknownFiling Date2013-01-17Publication Date2017-03-22
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Patent
Publication NumberNZ 628433 AStatusPatent ApplicationAvailabilityUnknownFiling Date2013-01-17Publication Date2017-02-24
The present disclosure relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Publication
PubMed ID27656328Published Date2016-08-01JournalJournal of clinical & cellular immunology, 2016-08-01, Volume 7
Manipulation of immune system toward the rejection of established cancers has become the standard of care in some patients. Here we propose the development of an autologous cancer vaccine, inCVAX, for the treatment of hepatocellular cancer (HCC). inCVAX is based on the induction of local immunogenic cancer cell death combined with local dendritic cell stimulation by intratumoral injection of the immune-activator -dihydro-galacto-chitosan (GC). In a first set of experiments, cellular and molec…
Patent
Publication NumberHK 1210019 A1StatusIssued PatentAvailabilityUnknownFiling Date2015-10-30Publication Date2016-04-15
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Publication
PubMed ID25633839Published Date2015-04-10JournalCancer letters, 2015-04-10, Volume 359
A novel, promising potential cancer vaccine strategy was proposed to use a two-injection procedure for solid tumors to prompt the immune system to identify and systemically eliminate primary and metastatic cancers. The two-injection procedure consists of local photothermal application on a selected tumor intended to liberate whole cell tumor antigens, followed by a local injection of an immunoadjuvant that consists of a semi-synthetic functionalized glucosamine polymer, N-dihydro-galacto-chit…
Patent
Publication NumberMX 2014008702 AStatusPatent ApplicationAvailabilityUnknownFiling Date2013-01-17Publication Date2015-04-08
The present invention relates generally to therapeutic compositions comprising chitosan- derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Publication
PubMed ID25977192Published Date2015-04-01JournalDiscovery medicine, 2015-04-01, Volume 19
Since the invention of Coley's toxin by William Coley in early 1900s, the path for cancer immunotherapy has been a convoluted one. Although still not considered standard of care, with the FDA approval of trastuzumab, Provenge and ipilimumab, the medical and scientific community has started to embrace the possibility that immunotherapy could be a new hope for cancer patients with otherwise untreatable metastatic diseases. This review aims to summarize the development of some major strategies i…
We found 27 documents that match your Search
Publications: 5
Patents: 19
SEC Filings: 3

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in